drugset
drugset / Trial / NCT02914262

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

NCT02914262 ↗

Phase 1 Completed 40 enrolled Aerpio Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

This will be a double-blind, randomized, placebo-controlled, single ascending dose, Phase I study in healthy male subjects.

Timeline

Start
2016-08
Primary completion
2016-11
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AKB-4924 Unknown 20 mg Oral
Subject AKB-4924 Unknown 60 mg Oral
Subject AKB-4924 Unknown 120 mg Oral
Subject AKB-4924 Unknown 240 mg Oral
Subject AKB-4924 Unknown 360 mg Oral
Subject AKB-4924 Unknown 480 mg Oral

Indications

inflammatory bowel disease